Skip to main content
SLAS2024 Main banner
Sartorius Ad
Back

Mark Ding, MD (he/him/his)

Eli Lilly and Company, California, United States

Dr. Ding is a highly accomplished professional in the field of medicinal chemistry synthesis and automation with a distinguished background. He holds a medical doctoral degree from Tianjin Medical University and has accumulated an impressive 15 years of experience in the dynamic drug discovery industry.

Before joining Eli Lilly, Dr. Ding worked at the NCATS/NIH ASPIRE team, playing a pivotal role in the collaboration between Eli Lilly and NCATS/NIH for the integration and development of the Indigo and Chemspeed chemistry automation platform at L2S2. His expertise extends to chemistry automation platform development, showcasing a profound understanding of cutting-edge technologies and innovative strategies.

Recently, he led the effort to build sample management capabilities at Eli Lilly Biotechnology Center in San Diego, where he heads the team in accomplishing the optimization of the DMTA cycle. Dr. Ding's commitment to excellence and passion for advancing the field underscore his reputation as a leader in medicinal chemistry and automation.

Disclosure information not submitted.

Presentation(s):